BR Broadridge Financial Solutions Inc

$228.40

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Broadridge Financial Solutions Inc

Broadridge Financial Solutions is a public corporate services company founded in 2007 as a spin-off from Automatic Data Processing. The main business of Broadridge is as a service provider supplying public companies with proxy statements, annual reports and other financial documents, and shareholder communications solutions, such as virtual annual meetings.

Website: https://www.broadridge.com

Sector
TRADE & SERVICES
Industry
SERVICES-BUSINESS SERVICES, NEC
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
June
CIK
1383312
Address
1981 MARCUS AVENUE, LAKE SUCCESS, NY, US
Valuation
Market Cap
$27.60B
P/E Ratio
36.91
PEG Ratio
1.67
Price to Book
12.39
Performance
EPS
$6.39
Dividend Yield
1.49%
Profit Margin
11.40%
ROE
35.30%
Technicals
50D MA
$235.93
200D MA
$223.37
52W High
$247.01
52W Low
$185.33
Fundamentals
Shares Outstanding
117M
Target Price
$243.93
Beta
1.07

BR EPS Estimates vs Actual

● Estimated
● Actual

BR News & Sentiment

Nov 18, 2025 • Benzinga NEUTRAL
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Nov 18, 2025 • GlobeNewswire NEUTRAL
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Nov 13, 2025 • Benzinga NEUTRAL
Piedmont Realty Trust Announces Pricing of Senior Notes Offering - Piedmont Realty Trust ( NYSE:PDM )
Atlanta, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Piedmont Realty Trust, Inc. ( the "Company" or "Piedmont" ) ( NYSE:PDM ) announced today that its operating partnership, Piedmont Operating Partnership, LP ( the "Operating Partnership" ) , has priced an offering of $400 million aggregate principal ...
Nov 13, 2025 • GlobeNewswire NEUTRAL
Piedmont Realty Trust Announces Pricing of Senior Notes Offering
Atlanta, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Piedmont Realty Trust, Inc. ( the "Company" or "Piedmont" ) ( NYSE:PDM ) announced today that its operating partnership, Piedmont Operating Partnership, LP ( the "Operating Partnership" ) , has priced an offering of $400 million aggregate principal ...
Nov 13, 2025 • Benzinga NEUTRAL
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Annexon ( NASDAQ:ANNX )
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( "Annexon" ) ( NASDAQ:ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the ...
Nov 13, 2025 • GlobeNewswire NEUTRAL
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
BRISBANE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( "Annexon" ) ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the ...
Sentiment Snapshot

Average Sentiment Score:

0.090
50 articles with scored sentiment

Overall Sentiment:

Neutral

BR Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
0.05 Surprise
  • Reported EPS: $3.55
  • Estimate: $3.50
  • Whisper: —
  • Surprise %: 1.4%
May 01, 2025
Mar 31, 2025 (Pre market)
0.03 Surprise
  • Reported EPS: $2.44
  • Estimate: $2.41
  • Whisper: —
  • Surprise %: 1.2%
Jan 31, 2025
Dec 31, 2024 (Pre market)
0.07 Surprise
  • Reported EPS: $1.56
  • Estimate: $1.49
  • Whisper: —
  • Surprise %: 4.7%
Nov 05, 2024
Sep 30, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $1.00
  • Estimate: $0.97
  • Whisper: —
  • Surprise %: 3.1%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $3.50
  • Estimate: $3.49
  • Whisper: —
  • Surprise %: 0.3%
May 08, 2024
Mar 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $2.23
  • Estimate: $2.24
  • Whisper: —
  • Surprise %: -0.5%
Feb 01, 2024
Dec 31, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.89
  • Whisper: —
  • Surprise %: 3.4%
Nov 02, 2023
Sep 30, 2023 (Pre market)
0.12 Surprise
  • Reported EPS: $1.09
  • Estimate: $0.97
  • Whisper: —
  • Surprise %: 12.4%
Aug 08, 2023
Jun 30, 2023 (Pre market)
0.11 Surprise
  • Reported EPS: $3.21
  • Estimate: $3.10
  • Whisper: —
  • Surprise %: 3.5%

Financials